Pancreatic Cancer
Pancreatic cancer patients responded well to oral S-1 combined with gemcitabine
Published in Health and Medicine Week, August 7th, 2006
"We conducted a phase II trial of GEM with S-1, oral fluorouracil (5-FU) prodrug tegafur combined with two modulators, 5-chloro-2,4-dihydroxypyridine and potassium oxonate, to evaluate the activity and toxicity of such a combination in metastatic pancreatic cancer (MPC) patients. Patients who had pathologically proven pancreatic cancer with metastatic lesions were eligible candidates for entry into the study," scientists writing in the British Journal of Cancer reported.
"S-1 was given orally (30 mg/m2) b.i.d. for 14...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health and Medicine Week
More Articles from Health and Medicine Week
- Amnesia Research
Study on mechanism of amnesia-inducing drug sheds light on how we form new memories - Fibromyalgia
Fibromyalgia symptoms are improved with acupuncture - Fitness & Wellness
Motivational factors are key to increasing youth physical activity through sports - Tourette Syndrome
Tourette syndrome severity linked to maternal smoking - Addiction Medicine
Concurrent use of alcohol and prescription drugs were studied in a university population - Addiction Medicine
Social influences on adolescent alcohol use are explored - More from this issue of Health and Medicine Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
